What is CARGO Therapeutics, Inc. Common Stock (CRGX)?

CARGO Therapeutics, Inc. Common Stock (CRGX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is CRGX's price-to-earnings (PE) ratio?

CRGX's trailing twelve-month PE ratio is -1.20, based on current price and earnings per share data available on Stocks360.

CARGO Therapeutics, Inc. Common Stock (CRGX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

-1.20

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.29

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

CARGO Therapeutics, Inc. Common Stock (CRGX) is a publicly traded company in the Healthcare sector. Trailing PE -1.20. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Aug 6, 2025

EPS $-0.27 vs est. $-0.38

Beat by $0.11

Proprietary Signals

Signal snapshot temporarily unavailable.

About CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.20×
P/S (TTM)	0.00×
P/B	0.56×
PEG	0.04×
P/FCF (TTM)	-1.50×
EV / EBITDA	-1.13×
EV / Sales	0.00×
Earnings Yield	-83.33%
Free Cash Flow Yield	-66.70%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$181.23M
Net Income (TTM)	-$180.15M
Free Cash Flow (TTM)	-$144.19M
Net Debt	-$34.95M
Working Capital	$319.99M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-43.76%
Return on Invested Capital	-48.09%